Considering its upstream inhibitory activity on the inflammatory cascade, tezepelumab inhibits the TSLP-mediated activation of dendritic cells and ILC2 cells (primarily involved in type 2 asthma), Th17 cells (primarily involved in neutrophilic asthma), as well as mast cells, smooth muscle cells, and fibroblasts in paucigranulocytic asthma. This evidence concerns the gene TSLP and asthma.